Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus
November 02, 2009 00:01 ET | Human Genome Sciences
ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary...
Benlysta Shatters Market Expectations and Upholds Cutting Edge Information's Forecast
July 23, 2009 10:04 ET | Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - July 23, 2009) - Benlysta, an experimental treatment for lupus, recently surprised many industry observers with positive clinical news. On Monday, shares...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
July 20, 2009 00:01 ET | Human Genome Sciences, Inc.
ROCKVILLE, MD and LONDON--(Marketwire - July 20, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab, formerly...